Beranda › Penyakit Hati › Virginia
Uji klinis Penyakit Hati di Virginia
6 studi untuk Penyakit Hati mencari peserta di lokasi di Virginia.
Kota di Virginia
Teks studi resmi (Bahasa Inggris)
A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)
- GI Alliance Richmond, Richmond
- GI Select Health Research, Richmond
Menerima pesertaFase 2
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 9 Sep 2026 · NCT07288138A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- dan 1 lainnya
Menerima pesertaFase 3
Usia 18 hingga 80 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06318169A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
- 89bio Clinical Study Site, Richmond
Menerima pesertaFase 3
Usia 18 hingga 75 · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06419374A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma
- Clinical Trial Site, Richmond
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Jun 2026 · NCT06600321Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
- Hunter Holmes McGuire VA Medical Center, Richmond
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06464952A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- Virginia Commonwealth University, Richmond
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Des 2025 · NCT06619561Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.